Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Nuclear Medicine
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1447500
This article is part of the Research Topic Recent Advances in Radiotheranostics View all 4 articles

Diagnostic Value of 68 Ga-NOTA-MAL-Cys-MZHER2:342 PET/CT Imaging for HER2-positive Lung Adenocarcinoma

Provisionally accepted
Shu Li Shu Li 1Ke Wang Ke Wang 2Xue Zhu Xue Zhu 2Donghui PAN Donghui PAN 2Ling Wang Ling Wang 2Xu Guo Xu Guo 3Xiaomin Gao Xiaomin Gao 1Qing Luo Qing Luo 1Xun Wang Xun Wang 1*
  • 1 Wuxi Medical College, Jiangnan University, Wuxi, China
  • 2 Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu Province, China
  • 3 Wuxi Maternity and Child Health Care Hospital, Wuxi, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    The human epidermal growth factor receptor 2 gene (HER2) has been identified as a potential therapeutic target in lung adenocarcinoma (LUAD). Non-invasive Positron Emission Tomography (PET) imaging provides a reliable strategy for in vivo determination of HER2 expression through whole-body detection of abnormalities. The PET tracer 68 Ga-NOTA-MAL-Cys-MZHER2:342 has shown promising results for HER2-positive breast and gastric cancers. This study aims to evaluate the performance of 68 Ga-NOTA-MAL-Cys-MZHER2:342 in vitro and in vivo models, as well as in clinical patients with HER2-positive LUAD.Methods: NOTA-MAL-Cys-MZHER2:342 was synthesized and labeled with 68 Ga. Cell uptake, cell binding ability, and stability studies of 68 Ga-NOTA-MAL-Cys-MZHER2:342 were assessed both in Calu-3 Lung cancer (LC) cell line and in normal mice. In vivo assessment in tumor-bearing mice was conducted using microPET imaging and biodistribution experiments. Additionally, preliminary PET/CT imaging analysis was performed on HER2-positive lung cancer patients.Results: 68 Ga-NOTA-MAL-Cys-MZHER2:342 was prepared with a radiochemical purity exceeding 95%. The tracer demonstrated high cell uptake in HER2-overexpressing Calu-3 cells, with an IC50 of 158.9 adequate 1.73 nM. Good stability was exhibited both in vitro and in vivo. MicroPET imaging of Calu-3-bearing mice revealed high tumor uptake and notable tumor-to-background ratios. Positive outcomes were also observed in two HER2-positive LUAD patients.

    Keywords: 68 Ga-NOTA-MAL-Cys-MZHER2:342, 18 F-FDG, PET, lung cancer, HER2 68 Ga-NOTA-MAL-Cys-MZHER2:342 demonstrated satisfactory stability, Sensitivity, and specificity. These findings suggest that 68 Ga-NOTA-MAL-Cys-MZHER2:342 PET/CT imaging provides a novel tool for non-invasive visual assessment of HER2 expression in LUAD patients

    Received: 11 Jun 2024; Accepted: 30 Jul 2024.

    Copyright: © 2024 Li, Wang, Zhu, PAN, Wang, Guo, Gao, Luo and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xun Wang, Wuxi Medical College, Jiangnan University, Wuxi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.